56621-90-0Relevant articles and documents
Synthesis and tunable ion-recognition properties of novel macrocyclic triamides
Ge, Ziyi,Zhang, Xingye,Chen, Shaojie,Liu, Ying,Peng, Ruixiang,Yokazawa, Tsutomu
, p. 5730 - 5738 (2014)
In this work, we report synthesis of rigid macrocyclic triamides and their tunable ion-recognition properties as selective anion and metal receptors. Diphenylacetylene-containing cyclic triamide CTA-1b and three cyclic triamides bearing functional methoxy
cGAS ANTAGONIST COMPOUNDS
-
Paragraph 0267, (2017/11/06)
Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases
Kawada, Hiroyoshi,Kador, Peter F.
, p. 8796 - 8805 (2015/12/09)
Neurodegenerative diseases are associated with oxidative stress that is induced by the presence of reactive oxygen species and the abnormal cellular accumulation of transition metals. Here, a new series of orally bioavailable multifunctional antioxidants (MFAO-2s) possessing a 2-diacetylamino-5-hydroxypyrimidine moiety is described. These MFAO-2s demonstrate both free radical and metal attenuating properties that are similar to the original published MFAO-1s that are based on 1-N,N′-dimethylsulfamoyl-1-4-(2-pyrimidyl)piperazine. Oral bioavailability studies in C57BL/6 mice demonstrate that the MFAO-2s accumulate in the brain at significantly higher levels than the MFAO-1s while achieving similar neural retina levels. The MFAO-2s protect human neuroblastoma and retinal pigmented epithelial cells against hydroxyl radicals in a dose-dependent manner by maintaining cell viability and intracellular glutathione levels. The MFAO-2s outperform clioquinol, a metal attenuator that has been investigated for the treatment of Alzheimer's disease.